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BACKGROUND: White matter abnormalities are a common feature of aging and Alzheimer disease, and tend to be more severe
among Black individuals. However, the extent to which white matter abnormalities relate to amyloid deposition, a marker of
Alzheimer pathology, remains unclear. This cross-sectional study examined the association of white matter abnormalities with
cortical amyloid in a community sample of older adults without dementia and examined the moderating effect of race.
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METHODS AND RESULTS: Participants from the ARIC-PET (Atherosclerosis Risk in Communities-Positron Emission Tomography)
study underwent brain magnetic resonance imaging, which quantified white matter hyperintensity volume and microstructural
integrity using diffusion tensor imaging. Participants received florbetapir positron emission tomography imaging to measure
brain amyloid. Associations between measures of white matter structure and elevated amyloid status were examined using
multivariable logistic regression. Among 322 participants (43% Black), each SD increase in white matter hyperintensity volume
was associated with a greater odds of elevated amyloid (odds ratio [OR], 1.37; 95% CI, 1.03–1.83) after adjusting for demographic and cardiovascular risk factors. In race-stratified analyses, a greater white matter hyperintensity volume was more
strongly associated with elevated amyloid among Black participants (OR, 2.00; 95% CI, 1.15–3.50), compared with White
participants (OR, 1.29; 95% CI, 0.89–1.89). However, the race interaction was not statistically significant (P interaction=0.09).
We found no association between white matter microstructure and elevated amyloid.
CONCLUSIONS: The results suggest a modest positive relationship between white matter hyperintensity and elevated amyloid
in older adults without dementia. Although the results indicate that this association is nonsignificantly stronger among Black
participants, these findings will need to be confirmed or refuted using larger multiracial cohorts.
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hite matter dysfunction is a pervasive feature of Alzheimer disease (AD) that has been
consistently associated with cognitive decline
and symptomatic progression.1 Magnetic resonance
imaging (MRI)–
defined white matter hyperintensities
(WMHs) and white matter microstructural abnormalities
often emerge one or more decades before the onset
of clinically defined dementia, even in relatively younger
individuals with autosomal dominant AD and minimal
vascular disease.2,3 Cerebral small vessel disease is

believed to be a primary cause of white matter abnormalities, and there is accumulating support for a bidirectional relationship between cerebral small vessel
disease and AD pathology, including amyloid-ß.4
A 2017 systematic review examining the relationship between WMHs and cortical amyloid5 concluded
that the association between positron emission tomography (PET)–defined amyloid and WMH volume
was not consistently supported. However, several recent studies with larger sample sizes (compared with
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most previous studies) have found a modest positive
association between WMH volume and cortical amyloid levels in individuals without dementia.2,6 While
these findings hint at a connection between cerebral
small vessel disease and cortical amyloid in the preclinical and/or prodromal phase of AD, it remains unknown whether these results translate to non-White/
European populations with differing vascular risk profiles, lifetime environmental exposures, and AD genetic
architecture. Thus, there is a clear need to understand
the relationship between white matter abnormalities
and amyloid accumulation, particularly among Black
older adults given that: (1) the prevalence of cerebrovascular disease, vascular risk factors, and dementia
is higher in this group, and (2) white matter abnormalities tend to be more severe in Black, compared with
White, older adults.7 To begin to understand whether
white matter structural abnormalities and amyloid co-
occur similarly among these race groups, the current
study examined the association of WMH volume and
WM microstructural integrity with cortical amyloid in
a community sample of Black and White older adults
without dementia in the ARIC (Atherosclerosis Risk in
Communities) study.

METHODS
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The data, analytic methods, and study materials will
be made available to other researchers for purposes
of reproducing the results or replicating the procedure in accordance with ARIC study policies. Data
from the ARIC study can be accessed, with appropriate approvals, through the National Heart, Lung, and
Blood Institute’s Biospecimen and Data Repository
Information Coordinating Center (https://biolincc.nhlbi.
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nih.gov/home/) or by contacting the ARIC Coordinating
Center.

Study Design and Participants
The ARIC study is a community-based cohort study
that enrolled 15 792 participants from 4 US communities upon its initiation (1987–1989).8 Of the 6538 participants who attended ARIC visit 5 (2011–2013), 1978
were selected to undergo brain MRI (Data S1). We used
available data from 346 of participants with MRI scans
who underwent florbetapir PET imaging as part of the
ARIC-PET study.9 Study inclusion/exclusion criteria are
outlined in Figure 1A. ARIC study protocols were approved by the institutional review boards at each participating center. All participants gave written informed
consent at each study visit.

Brain MRI and PET Imaging
Brain MRI scans were conducted using a 3T scanner. Images were analyzed at the ARIC MRI Reading
Center (Mayo Clinic). Magnetization-
prepared
rapid acquisition gradient echo (MP-
R AGE), axial
T2*gradient echo, axial T2 fluid-attenuated inversion
recovery (FLAIR), and axial diffusion tensor imaging
(DTI) sequences were obtained from all participants.
WMH volumes were derived from FLAIR images
using a quantitative computer-
aided segmentation program to measure the volumetric burden of
leukoaraiosis, defined as increased signal intensity
within white matter.10 The computer-aided segmentation program is an update of the in-house semiautomated method previously described by Raz et
al.10 WMHs were segmented on native 2-dimensional
FLAIR images using an automated seed initialization

Figure 1. Study inclusion and exclusion criteria and white matter hyperintensity (WMH) volume by race.
ARIC indicates Atherosclerosis Risk in Communities; MRI, magnetic resonance imaging; and PET, positron emission tomography.
Figure created with BioRender.com.
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based on location (spatial priors), intensity relative to
the distribution of grey matter intensity values, and
the intensity relative to its local neighborhood. To
reduce the number of false-positive segmentations
of WMHs from FLAIR images, the MP-R AGE image
was resampled in FLAIR space and the MP-R AGE
segmentation was used to generate a white matter
mask.10 Using this method, a continuous measure of
WMH volume was derived. T2*gradient echo scans
were used to identify lobar and subcortical cerebral
microbleeds (CMBs). DTI measures of fractional anisotropy (FA) and mean diffusivity (MD) were used to
assess white matter microstructural integrity. Lower
FA and higher MD are accepted as measures of reduced white matter integrity. Our primary analysis
examined composite FA and MD measures derived
using 4 white matter tracts known to be affected
early in AD: the cingulate gyrus cingulum, hippocampal cingulum, superior longitudinal fasciculus, and
splenium of the corpus callosum.11–13 Using these
tracts, we derived a general factor for FA and MD
from the first unrotated principal component of the
standardized FA and MD values (Table S1).
Florbetapir PET neuroimaging was used to identify participants with elevated cortical amyloid. PET
scans were conducted within 1 year of brain MRIs
and were coregistered with MRI MP-
R AGE sequences at 3 ARIC-PET sites. We used a 20-minute
(4×5 minute) uptake scan that was obtained starting
50 minutes after intravenous injection of the florbetapir isotope. The Wong laboratory (D.F.W. and Y.Z.) at
Johns Hopkins University reviewed images for quality and calculated standardized uptake value ratios
using a cerebellar gray matter reference region. The
current analyses used a global measure of cortical
florbetapir uptake defined as the volume-dependent
weighted averages of 9 regions. Elevated cortical
amyloid (standardized uptake value ratio >1.2) was
defined a priori based on the ARIC-
PET sample
median, consistent with previous ARIC-
PET studies.9 See Data S1 for further description of the PET
protocol.

Covariate and Clinical Assessment
Age at index visit (visit 5) and participant demographic data (race [Black/White], education, sex) reported by participants at ARIC visit 1 were used as
covariates. The TaqMan assay (Applied Biosystems)
was used to define APOE genotype (0 versus ≥1
APOEε4 alleles). Annual combined family income
was assessed at visit 4 (1996–1998) based on self-
report. All other covariates were defined at visit 5.
Body mass index was defined based on participant
height and measured weight. Hypertension was defined based on measured systolic and diastolic blood
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pressure >140/90 mm/Hg or use of antihypertensive
medication. Diabetes mellitus was defined based on
self-report of physician diagnosis, diabetes mellitus
medication use, or glycated hemoglobin level ≥6.5%.
History of coronary heart disease was defined by
self-report at visit 1 and adjudicated between visits
1 and 5. Current smoking status was defined based
on self-report. Participants’ cognitive status (normal/
mild cognitive impairment) was defined based on
National Institute on Aging (NIA) and the Alzheimer’s
Association (AA)/Diagnostic and Statistical Manual of
Mental Disorders, Fifth Edition (DSM-5) criteria (Data
S1). Participants who met criteria for dementia were
not included in the ARIC-PET study.

Statistical Analysis
We used multivariable logistic regression to examine the association of WMH volume and DTI FA/
MD (independent variables) with elevated cortical amyloid (dependent variable). We examined 2
models. The first model included demographic risk
factors (age, study center, race, sex, education,
and APOE genotype). The second model additionally adjusted for cardiovascular risk factors (CRFs),
ie, body mass index, diabetes mellitus, hypertension, coronary heart disease, and current smoking
status. Based on recent findings suggesting that
CMBs may account for the relationship between
WMHs and amyloid, 2 we repeated the primary
analyses after excluding participants with any/
lobar CMBs. To examine the modifying effect of
race on the white matter-a myloid relationship, we
also examined race-by-W MH and race-by-FA/MD
interaction terms and conducted stratified analyses. WMH volume and DTI FA/MD were modeled
as continuous variables and divided into quartiles
to examine nonlinear associations. WMH quartiles
were defined after WMH volume was normalized
for intracranial volume. Analyses examining WMH
volume as a continuous variable were adjusted for
intracranial volume. Additionally, WMH volumes
were log-transformed because of skewness. A 2-
sided P value <0.05 was used to designate statistical significance. Analyses were conducted using
Stata version 14 (StataCorp).

RESULTS
A total of 338 participants were included in the final
analytic sample (age 76 years [SD, 5 years]; 43%
[N=144] were of Black race and 57% [N=191] were
women). A total of 51% (N=173) of the sample was
amyloid-positive; 64% (N=92) of Black participants
and 42% (N=81) of White participants were amyloid-
positive (Figure S1). Sixteen participants were missing
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≥1 CRF covariates and were not included in the CRF-
adjusted model. Full sample characteristics are displayed in Table S2. WMH volume did not significantly
differ between Black and White participants (Mann-
Whitney U test, z=1.50; P=0.13), although there were
more Black participants at the highest end of the distribution (Figure 1B).
In a model adjusted for demographic characteristics, participants with greater WMH volume had a
higher odds of elevated cortical amyloid (OR, 1.36 per
SD increase WMH volume; 95% CI, 1.03–1.79; Table).
The results were similar after adjustment for CRFs,
after excluding participants with ≥1 CMB or lobar CMB
(Table S3), and after additionally adjusting for the presence of cerebral infarcts (Table S4). In race-stratified
analyses, each SD increase in WMH volume doubled
the odds of elevated cortical amyloid among Black participants (Table). The association between WMH volume and amyloid did not extend to White participants,
however. A formal assessment of effect modification
by race did not yield statistical significance (P interaction=0.09). Overall, the results were similar when WMH
volume was examined by quartile (Table; Figure S2).
Use of race-specific WMH quartiles did not change
these results (Figure 2A and 2B; Table S5). Results
were similar using a common alternative threshold
for elevated amyloid (standardized uptake value ratio
>1.11; Table S6).
In post hoc sensitivity analyses that examined
the effect of adjusting for midlife vascular risk factors
(which have been previously linked to late-life WMH
and amyloid levels), the association between WMH
and elevated amyloid persisted in the full sample
(Table S7). However, the magnitude of the association
was attenuated among Black participants, suggesting
that midlife vascular risk factors account, in part, for the
WMH-amyloid relationship in this group. Adding combined annual family income (a proxy of socioeconomic
status) to the primary model did not meaningfully
change the results (Table; Table S8). The relationship
between greater WMH volume and elevated amyloid
among Black participants was maintained when 7 participants with outlier WMH volumes (>3 SD above the
total sample mean) were excluded (odds ratio [OR],
1.94 [95% CI, 1.06–3.55] P=0.03; N=132) and when
only cognitively normal Black participants were examined (OR, 2.07 [95% CI, 1.11–3.86] P=0.02; N=102). An
examination of region-specific amyloid found the WMH
volume-amyloid association was strongest in the precuneus region (Figure 2C). Results were similar among
race groups.
General and tract-specific DTI measures of white
matter microstructural integrity were unrelated to elevated cortical amyloid in demographically adjusted
and CRF-adjusted models, and in race-stratified analyses (Tables S9–S12).
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DISCUSSION
The current study provides evidence for a positive
relationship between brain WMH volume and cortical amyloid in older adults without dementia. This association occurred independent of CMBs, a marker
of cerebral amyloid angiopathy, and tended to be
stronger among Black participants, although not significantly. In contrast to WMH volume, general and
tract-specific measures of DTI white matter microstructure were unrelated to amyloid status.
Previous studies of the relationship between WMH
volume and cortical amyloid have been conducted in
European, US White, or Korean populations and have
yielded mixed results.5 Among studies showing positive
results, modest effect sizes were typically observed,6
comparable with that found in the current analysis of
White participants. By comparison, our analysis revealed
a strong association between WMH volume and cortical amyloid in Black participants, even among the subset of Black participants without cognitive impairment.
This finding is of particular relevance to understanding
of the role that race, perhaps a proxy for lifelong social
experiences and physiological and environmental exposures, may play in the development of AD. Black adults
are disproportionately affected by Alzheimer dementia
compared with their age-adjusted White counterparts.14
Although the causes of this disparity are not yet fully understood, there likely exist a multitude of factors, social,
environmental, and possibly biologic.
While causal inferences cannot be derived from
this cross-sectional analysis, the findings do suggest
a connection between cerebrovascular processes
underlying WMHs and amyloid accumulation that is
independent of cardiovascular risk factors (late-
life
and midlife), cerebral infarcts, and cerebral amyloid
angiopathy. If there is a causal relationship between
cerebrovascular dysfunction and amyloid accumulation, as has been suggested elsewhere,4 the strong
association between WMHs and amyloid deposition in
Black older adults may be relevant to understanding
the pattern of increased dementia risk in this population. Regarding predictors of amyloid status, we found
that demographic factors accounted for the bulk of
the variance in amyloid status in the full sample, and
in race-stratified analyses. In contrast, prevalent (late-
life) CRFs did not account for much additional variance
in amyloid status and do not appear to account for
the association between WMH volume and amyloid.
However, the presence of midlife vascular risk factors did account in part for the stronger association
between WMH volume and elevated amyloid among
Black participants, suggesting that distal health factors, rather than race itself, may contribute to group
differences in the magnitude of the WMH-
amyloid
association. Similar to distal health factors, social
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Figure 2. Race-and brain region–specific associations between white matter hyperintensity
(WMH) volume and elevated cortical amyloid.
All models were adjusted for intracranial volume, age, center, race, sex, education, APOE ε4 status, and
late-life (visit 5) body mass index, diabetes mellitus, hypertension, coronary heart disease, and current
smoking status (ie, model 2). A, B, The adjusted probability and standard error of elevated cortical amyloid
for each quartile of WMH volume, calculated using logistic regression. Race-specific WMH quartiles were
used for analyses. C, The adjusted odds ratio (OR) of regional elevated cortical amyloid per SD increase in
WMH volume, calculated using logistic regression. The adjusted OR for Black participants was imprecise:
OR, 25.2 (95% CI, 1.9–339.8); coronary heart disease and smoking status covariates were excluded
because they predicted the outcome perfectly.*P<0.05; **P<0.01.

determinants of health (eg, socioeconomic status/position, stress/discrimination, access to health care, and
neighborhood and environmental exposures), which

tend to differ between Black and White individuals living within the United States, may account for the stronger link between WMH and amyloid observed in Black
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participants. Although the current study attempted to
account for socioeconomic status using a crude proxy
measure (family income level), future work that more
carefully accounts for social health determinants will be
needed to identify drivers of disparities in AD.
The lack of association between white matter microstructural integrity and amyloid-positive status also
deserves some consideration. While studies examining
the association of PET-and cerebrospinal fluid-defined
amyloid levels with DTI measures of FA and MD have
yielded mixed results, a more consistent association
has emerged between DTI white matter microstructure
and tau pathology, particularly for white matter tracts
in areas that experience early tau pathology.15 If the
associations between amyloid levels and white matter
microstructural integrity are indeed driven by tau pathology, it is possible that the amyloid-positive participants in the present study are not advanced enough in
their disease, ie, do not have enough tau neurofibrillary
tangle pathology, to show amyloid-DTI associations.
The current results should be interpreted within the
context of several limitations. First, the study is limited
by its cross-sectional design. Understanding the time
course of the amyloid-WMH relationship with respect to
the clinical manifestations of symptoms will be essential
in advancing the understanding of AD pathophysiology.
Second, because the majority of Black participants who
underwent amyloid PET neuroimaging were from a single study site (Jackson, Mississippi), it is possible that the
demonstrated race-specific findings are attributable to a
nondescribed phenomenon specific to the geographic
region. Thus, additional multiethnic community-
based
studies in other geographic regions are required to confirm the generalizability of our findings. Third, the lack
of region-
specific WMH information limited the ability
to look at how WMH occurring in specific brain regions
related to amyloid levels. Finally, selection into the ARIC-
PET substudy, which excluded participants with dementia and participants with MRI and PET contraindications,
may have introduced a positive selection bias for those
participants who have generally better cardiovascular
health compared with the population in totum. This selection may also affect the generalizability of the findings.
Within the context of these limitations, the current
study provides support for a relationship between
WMHs and elevated cortical amyloid in older adults
without dementia. This relationship was particularly
strong among Black participants. However, there was
no relationship between DTI-defined white matter microstructural integrity and cortical amyloid. These findings will need to be confirmed or refuted using larger
multiracial cohorts.
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Data S1.
Supplemental Methods
Participant selection for ARIC visit 5 brain MRI
Of the 6,528 participants who attended ARIC visit 5, 1,978 underwent a brain MRI. Participants were
selected based on the criteria listed below, as previously outlined in Knopman et al. (2015).16 Participants
with MRI contraindications were excluded from this selection. Participants were selected to receive a visit
5 brain MRI if they (1) received a brain MRI as part of the 2004-06 ARIC Brain MRI Ancillary Study, or
(2) demonstrated cognitive impairment, defined as a low Mini-Mental State Exam (MMSE) score (<21
for White and <19 for Black participants), two or more low cognitive domain scores at visit 5 (<-1.5
standard deviations) and cognitive decline on the Delayed Word Recall test, the Digit Symbol
Substitution test, or the Word Fluency test (<10th percentile of decline on serial testing on 1 or more tests
or <20th percentile on 2 or more tests). Additionally, we selected an age-stratified random sample of
cognitively intact participants with an age distribution that approximated that of cognitively impaired
participants.
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ARIC-PET florbetapir PET methods
Florbetapir PET imaging was conducted at the Washington County, MD, Jackson, MS, and Forsyth
County, NC study sites with Philips TruFlight, GE Discovery 690, and GE Discovery ST scanners,
respectively. Phantom scan with ~1mCi of F-18 were conducted throughout the course of the study to
ensure spatial uniformity and quantitative accuracy across study sites. To arrive at an effectively
equivalent spatial resolution of 8.30 mm for the three sites, PET images at the Washington County and
Forsyth County study sites were spatially smoothed. Images were analyzed at Reading center of the Wong
Lab located in the Johns Hopkins University Section of High-Resolution Brain PET Imaging, Department
of Radiology although no PET scans for ARIC were performed there. Consistent with the typical static
florbetapir PET imaging protocol as employed in ADNI 2, 4-frame dynamic images were used to derive
the mean of the 20-minute image acquisition. These mean PET images were then coregistered with
corresponding structural MRI images. Using SPM8 and VBM8 toolbox, MRI images were normalized to
the standard Montreal Neurologic Institute (MNI) space; the transformation parameters determined by
MRI spatial normalization were then applied to coregistered PET images for PET spatial normalization.
Thirty-four regions of interest were manually drawn on the MRI template in standard MNI space using
PMOD software (PMOD Technologies Ltd., Zurich, Switzerland). Standard uptake value ratio (SUVR)
images were calculated using the cerebellar gray as the reference region, and ROIs were applied to SUVR
images.9 The current analyses used a global measure of cortical florbetapir uptake defined as the volumedependent weighted averages of the orbitofrontal, prefrontal, and superior frontal lobes; the lateral
temporal, parietal, and occipital lobes; the precuneus, and the anterior cingulate, and the posterior
cingulate regions.
Cognitive classification
Dementia and mild cognitive impairment (MCI) at ARIC visit 5 were defined based on National Institute
on Aging-Alzheimer’s Association (NIA-AA) workgroup and Diagnostic and Statistical Manual of
Mental Disorders, 5th Edition (DSM-5) criteria 17–19 based on a comprehensive battery provided at visit 5,
data from repeated cognitive testing administered at ARIC visits 2, 4, and 5, and an informant interview
conducted at ARIC visit 5, which incorporated the Clinical Dementia Rating Scale (CDR) and Functional
Activities Questionnaire (FAQ). An algorithm used this information to classify participants as either
being cognitively normal, as meeting criteria for MCI, or as meeting criteria for dementia. An expert
panel of physicians and neuropsychologists then confirmed each of these classifications. An algorithmic
diagnosis of Dementia was defined as >1 cognitive domain worse than -1.5 Z, a CDR sum of boxes >3,
and a decline from the previous cognitive assessment that was below the 10th percentile on one or more

test, or below the 20th percentile on two or more tests in the repeated ARIC cognitive battery. Mild
cognitive impairment (MCI) was defined as at least one domain score worse than -1.5 Z, a CDR sum of
boxes between >0.5 and ≤3, an FAQ ≤5, and a decline on the repeated ARIC cognitive battery below the
10th percentile on one test or below the 20th percentile on two or more tests 20. Participants who did not
meet criteria for dementia or MCI were classified as cognitively normal.
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Table S1. Principal component analysis (PCA) for white matter tracts included in general
FA (gFA) and MD (gMD) composite scores.
White matter tract
Cingulate Gyrus Cingulum, Left
Cingulate Gyrus Cingulum, Right
Hippocampal Cingulate Gyrus, Left
Hippocampal Cingulate Gyrus, Right
Superior Longitudinal Fasciculus, Left
Superior Longitudinal Fasciculus, Right
Splenium of the Corpus Callosum
Eigenvalue
Proportion of variance

PC1 (FA)
0.43
0.42
0.38
0.38
0.37
0.34
0.32
3.06
44%

PC1 (MD)
0.40
0.41
0.34
0.36
0.38
0.39
0.36
5.03
72%

The factor scores for FA and MD derived from an unrotated principal component analysis of
standardized FA and MD values. The factor score captures the shared variance in white matter
integrity across multiple white matter tracts known to be affected in Alzheimer’s disease. N=336
(all participants with available DTI data).
Abbreviations: FA, fractional anisotropy; MD, mean diffusivity; PC1, first principal component
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Table S2. Baseline (Visit 5; 2011-13) participant characteristics.
Characteristic

Total Sample
(N = 338)

Black
Participants
(N = 144)

White
Participants
(N = 194)

Age
Female (%)
Black (%)

75.9 (5.4)
191 (57%)
144 (43%)

75.6 (5.1)
88 (61%)
--

76.2 (5.6)
103 (53%)
--

Washington County, Maryland
Forsyth County, North Carolina
Jackson, Mississippi

128 (38%)
72 (21%)
138 (41%)

3 (2%)
3 (2%)
138 (96%)

125 (64%)
69 (36%)
0 (0%)

Less than high school
High school/GED/vocational
College/graduate/professional

56 (17%)
145 (43%)
137 (41%)

30 (21%)
53 (37%)
61 (42%)

26 (13%)
92 (47%)
76 (39%)

0 (%)
1 (%)
2 (%)

235 (70%)
95 (28%)
8 (2%)

91 (63%)
48 (33%)
5 (3%)

144 (74%)
47 (24%)
3 (2%)

Demographic Variables

Center

Education (%)

APOEε4 alleles
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Clinical & Physiological Variables
Body mass index, kg/m2*
29.1 (5.4)
29.9 (5.3)
28.5 (5.4)
Total cholesterol, mg/dl 180.8 (39.2)
185.5 (41.6)
177.4 (37.0)
Hypertension*
241 (72%)
119 (83%)
122 (64%)
Diabetes mellitus
116 (35%)
54 (38%)
62 (32%)
*
Coronary heart disease
26 (8%)
6 (4%)
20 (11%)
Current smoker
17 (5%)
9 (6%)
8 (4%)
Cognitively normal
247 (73%)
106 (73%)
141 (73%)
Mild cognitive impairment
91 (27%)
53 (27%)
91 (27%)
Values are displayed as means (standard deviation) and frequencies (percentages). Black and white
participant characteristics were compared using independent-samples t-tests and chi-square tests.
*
Difference between black and white participants statistically significant (p < .05)

Table S3. The association of WMH volume with elevated cortical amyloid after excluding
participants with cerebral microbleeds (CMBs).
White Matter Hyperintensity
(WMH) Volume *

WMH Quartile 1, (reference)

Excluding
participants with any
CMBs
(Model 2)†
N=241
Elevated Amyloid
OR (95% CI)

P

Excluding
participants with
lobar CMBs
(Model 2)†
N=287
Elevated Amyloid
OR (95% CI)

P

1 (ref)

--

1 (ref)

--

WMH Quartile 2

1.43 (0.60, 3.39)

0.42

1.46 (0.68, 3.15)

0.34

WMH Quartile 3

0.88 (0.36, 2.15)

0.78

1.00 (0.46, 2.20)

0.99

WMH Quartile 4

2.95 (1.10, 7.92)

0.03

2.67 (1.15, 6.22)

0.02

WMH (log), Per 1 SD (continuous)

1.50 (1.04, 2.16)

0.03

1.49 (1.08, 2.05)

0.02

Among the 322 participants eligible for this analysis: N=78 had one or more CMB; N=30 had one or
more lobar CMB; N=3 had missing data for any CMB; N=5 had missing data for lobar CMB.
*
WMH volumes were quartiled after normalization for intracranial volume.
†
Model 2 is adjusted for intracranial volume, age, center, race, sex, education, APOE ε4 status, and latelife (visit 5) BMI, diabetes, hypertension, coronary heart disease, and current smoking status.
Abbreviations: CMB, cerebral microbleed; OR, odds ratio; SD, standard deviation.
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Table S4. The association of WMH volume with elevated cortical amyloid after adjusting for presence of cerebral infarct.
White Matter Hyperintensity
(WMH) Volume*

Q1, 0.5 to 7.5 cm3 (reference)

Full Sample
(Model 2 + cerebral
infarct)
N=322
Elevated Amyloid
OR (95% CI)

P

Black
(Model 2 + cerebral
infarct)
N=139
Elevated Amyloid
OR (95% CI)

P

White
(Model 2 + cerebral
infarct)
N=183
Elevated Amyloid
OR (95% CI)

P

1 (ref)

--

1 (ref)

--

1 (ref)

--

Q2, 6.1 to 13.0 cm3

1.32 (0.64, 2.71)

0.45

3.04 (0.87, 10.64)

0.08

0.97 (0.37, 2.49)

0.94

Q3, 9.5 to 21.8 cm3

1.02 (0.49, 2.15)

0.95

2.21 (0.60, 8.16)

0.23

0.68 (0.26, 1.81)

0.44

Q4, 15.8 to 133.5 cm3

2.12 (0.98, 4.61)

0.06

7.94 (1.72, 36.62)

0.008

1.63 (0.60, 4.40)

0.33
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WMH (log), Per 1 SD
1.36 (1.01, 1.82)
0.04
2.00 (1.11, 3.60)
0.02
1.29 (0.88, 1.88)
0.20
(continuous)
All models were adjusted for intracranial volume, age, center, race, sex, education, APOE ε4 status, and late-life (visit 5) BMI, diabetes,
hypertension, coronary heart disease, and current smoking status (i.e., Model 2) in addition to cerebral infarct (present/absent).
A total of 70 of the 322 participants (22%) included in this analysis had one or more infarct, including 31 (22%) infarcts among Black participants
and 39 (21%) infarcts among White participants.
Abbreviations: OR, odds ratio; Q1, quartile 1; Q2, quartile 2; Q3, quartile 3; Q4, quartile 4; SD, standard deviation.
*
WMH volumes were quartiled after normalization for intracranial volume. As a result, there is some overlap among quartiles for the provided
non-normalized WMH volumes

Table S5. The association of WMH volume with elevated cortical amyloid, stratified by
race using race-specific quartiles to define WMH burden.
White Matter Hyperintensity
(WMH) Volume*

Q1, 1.3 to 8.0 cm3 (reference)

Black
N=139
Elevated Amyloid
OR (95% CI)

P

1 (ref)

--

Q2, 6.6 to 12.8 cm3

2.52 (0.77, 8.26)

0.13

Q3, 9.9 to 20.3 cm3

2.47 (0.73, 8.31)

0.14

Q4, 19.2 to 133.5 cm3

6.67 (1.61, 27.68)

0.009

White Matter Hyperintensity
(WMH) Volume*

White
N=183
Elevated Amyloid
OR (95% CI)

Q1, 0.5 to 7.3 cm3 (reference)

P

1 (ref)

--

Q2, 5.9 to 11.4 cm3

0.71 (0.27, 1.92)

0.50

Q3, 9.4 to 21.6 cm3

0.81 (0.30, 2.19)

0.68

Q4, 15.8 to 89.4 cm3

1.24 (0.46, 3.35)

0.67
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All models were adjusted for age, center, race, sex, education, APOE ε4 status, and late-life (visit 5) BMI,
diabetes, hypertension, coronary heart disease, and current smoking status (i.e., Model 2). Race-specific
WMH quartiles were used for analyses.
*
WMH volumes were quartiled after normalization for intracranial volume. As a result, there is some
overlap among quartiles for the provided non-normalized WMH volumes.
Abbreviations: OR, odds ratio; Q1, quartile 1; Q2, quartile 2; Q3, quartile 3; Q4, quartile 4.

Table S6. The association of WMH volume with elevated cortical amyloid using an
alternative threshold for elevated amyloid (SUVR>1.11).
White Matter Hyperintensity
(WMH) Volume*

Q1, 0.5 to 7.5 cm3 (reference)

Model 1
N=338
Elevated Amyloid
OR (95% CI)

P

Model 2
N=322
Elevated Amyloid
OR (95% CI)

P

1 (ref)

--

1 (ref)

--

Q2, 6.1 to 13.0 cm3

1.60 (0.71, 3.60)

0.25

1.88 (0.79, 4.47)

0.15

Q3, 9.5 to 21.8 cm3

1.25 (0.56, 2.78)

0.58

1.24 (0.53, 2.88)

0.62

Q4, 15.8 to 133.5 cm3

2.61 (1.07, 6.41)

0.04

2.62 (1.04, 6.61)

0.04

WMH (log), Per 1 SD (continuous)

1.36 (0.97, 1.91)

0.07

1.35 (0.95, 1.93)

0.10

White Matter Hyperintensity
(WMH) Volume*

Q1, 0.5 to 7.5 cm3 (reference)

Black
(Model 2)
N=139
Elevated Amyloid
OR (95% CI)

P

White
(Model 2)
N=183
Elevated Amyloid
OR (95% CI)

P
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1 (ref)

--

1 (ref)

--

Q2, 6.1 to 13.0 cm3

34.26 (2.60, 451.93)

0.007

1.26 (0.46, 3.43)

0.66

Q3, 9.5 to 21.8 cm3

11.84 (1.25, 112.22)

0.03

0.86 (0.32, 2.30)

0.76

5.78E03 (18.41,
1.82E06)

0.003

1.39 (0.49, 3.89)

0.54

3.60 (1.26, 10.24)

0.02

1.20 (0.80, 1.79)

0.38

Q4, 15.8 to 133.5 cm3
WMH (log), Per 1 SD (continuous)

Model 1 is adjusted for intracranial volume, age, center, race, sex, education, and APOE ε4 status. Model
2 is additionally adjusted for late-life (visit 5) BMI, diabetes, hypertension, coronary heart disease, and
current smoking status. Sixteen participants included in model 1 were excluded from model 2 due to
missing one or more model 2 covariate. P-values for the WMH volume by race interaction term were 0.07
for the quartiled analysis and 0.13 for the continuous analysis. The current smoking covariate was omitted
from the analysis of Black participants because it predicted the outcome exactly.
Abbreviations: OR, odds ratio; Q1, quartile 1; Q2, quartile 2; Q3, quartile 3; Q4, quartile 4; SD, standard
deviation.
*
WMH volumes were quartiled after normalization for intracranial volume. As a result, there is some
overlap among quartiles for the provided non-normalized WMH volumes.

Table S7. The association of WMH volume with elevated cortical amyloid after adjusting for midlife vascular risk factors.
White Matter Hyperintensity
(WMH) Volume*

Q1, 0.5 to 7.5 cm3 (reference)

Full Sample
(Model 2 + midlife
vascular risk factors)
N=328
Elevated Amyloid
OR (95% CI)

P

Black
(Model 2 + midlife
vascular risk factors)
N= 140
Elevated Amyloid
OR (95% CI)

P

White
(Model 2 + midlife
vascular risk factors)
N= 185
Elevated Amyloid
OR (95% CI)

P

1 (ref)

--

1 (ref)

--

1 (ref)

--

Q2, 6.1 to 13.0 cm3

1.14 (0.56, 2.33)

0.72

2.70 (0.81, 8.95)

0.11

0.79 (0.31, 2.01)

0.62

Q3, 9.5 to 21.8 cm3

1.02 (0.49, 2.10)

0.97

2.05 (0.60, 7.02)

0.25

0.65 (0.25, 1.71)

0.38

Q4, 15.8 to 133.5 cm3

2.03 (0.96, 4.31)

0.06

4.76 (1.26, 17.91)

0.02

1.54 (0.58, 4.06)

0.38
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WMH (log), Per 1 SD
1.35 (1.01, 1.79)
0.04
1.66 (1.00, 2.76)
0.05
1.28 (0.88, 1.86)
0.20
(continuous)
All models were adjusted for intracranial volume, age, center, race, sex, education, and APOE ε4 status, and midlife (visit 1; 1987-89) BMI,
diabetes, hypertension, coronary heart disease, and current smoking status. Ten participants included in model 1 were excluded from this analysis
due to missing one or more covariate.
Abbreviations: OR, odds ratio; Q1, quartile 1; Q2, quartile 2; Q3, quartile 3; Q4, quartile 4; SD, standard deviation.
*
WMH volumes were quartiled after normalization for intracranial volume. As a result, there is some overlap among quartiles for the provided
non-normalized WMH volumes

Table S8. The association of WMH volume with elevated cortical amyloid, stratified by
race and additionally adjusted for family income.
White Matter Hyperintensity
(WMH) Volume*

Q1, 0.5 to 7.5 cm3 (reference)

Black
(Model 3)
N=133
Elevated Amyloid
OR (95% CI)

P

White
(Model 3)
N=176
Elevated Amyloid
OR (95% CI)

P

1 (ref)

--

1 (ref)

--

Q2, 6.1 to 13.0 cm3

2.95 (0.83, 10.46)

0.09

1.15 (0.43, 3.07)

0.78

Q3, 9.5 to 21.8 cm3

1.90 (0.52, 7.00)

0.33

0.72 (0.27, 1.94)

0.51

Q4, 15.8 to 133.5 cm3

9.66 (2.07, 45.02)

0.004

1.79 (0.65, 4.98)

0.26

WMH (log), Per 1 SD (continuous)

1.99 (1.13, 3.51)

0.02

1.30 (0.88, 1.91)

0.19

All models were adjusted for age, center, race, sex, education, APOE ε4 status, and late-life (visit 5) BMI,
diabetes, hypertension, coronary heart disease, current smoking status, and total combined annual family
income (i.e., Model 3). Thirteen participants included in model 2 were excluded from model 3 due to
missing household family income data.
Abbreviations: OR, odds ratio; Q1, quartile 1; Q2, quartile 2; Q3, quartile 3; Q4, quartile 4; SD, standard
deviation.
*
WMH volumes were quartiled after normalization for intracranial volume. As a result, there is some
overlap among quartiles for the provided non-normalized WMH volumes.
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Table S9. The association of white matter DTI gFA with elevated cortical amyloid.
General Fractional Anisotropy
(gFA)

P

Model 1
N=336
Elevated
Amyloid
OR (95% CI)

P

Model 2
N=320
Elevated
Amyloid
OR (95% CI)

1 (ref)

--

1 (ref)

--

Q2, -0.63, 0.03 Z

1.97 (1.06, 3.64)

0.03

1.80 (0.93, 3.49)

Q3, 0.06, 0.66 Z

1.21 (0.66, 2.22)

0.54

Q4, 0.66, 2.48 Z

1.05 (0.57, 1.93)

gFA, Per 1 SD (continuous)

0.99 (0.80, 1.23)

Q1, -3.57, -0.66 Z (reference)

General Fractional Anisotropy
(gFA)
Downloaded from http://ahajournals.org by on February 24, 2022

Q1, -3.57, -0.66 Z (reference)

Model 0
N=336
Elevated
Amyloid
OR (95% CI)

P

Model 3
N=307
Elevated
Amyloid
OR (95% CI)

P

1 (ref)

--

1 (ref)

--

0.08

1.59 (0.79, 3.20)

0.19

1.71 (0.83, 3.53)

0.15

1.31 (0.65, 2.61)

0.45

1.08 (0.51, 2.29)

0.83

1.12 (0.52, 2.39)

0.77

0.88

1.15 (0.56, 2.36)

0.71

1.00 (0.47, 2.13)

0.99

1.06 (0.49, 2.29)

0.89

0.95

1.03 (0.80, 1.33)

0.82

1.02 (0.78, 1.33)

0.90

1.03 (0.78, 1.36)

0.84

Black
(Model 0)
N=143
Elevated
Amyloid
OR (95% CI)

White
(Model 0)
N=193
Elevated
Amyloid
OR (95% CI)

P

Black
(Model 2)
N=138
Elevated
Amyloid
OR (95% CI)

P

White
(Model 2)
N=182
Elevated
Amyloid
OR (95% CI)

P

1 (ref)

--

1 (ref)

--

1 (ref)

--

1 (ref)

--

Q2, -0.63, 0.03 Z

2.41 (0.77, 7.59)

0.13

1.64 (0.76, 3.52)

0.21

2.09 (0.56, 7.78)

0.27

1.30 (0.54, 3.15)

0.56

Q3, 0.06, 0.66 Z

1.12 (0.40, 3.11)

0.83

0.99 (0.45, 2.22)

0.99

1.02 (0.29, 3.56)

0.97

1.01 (0.37, 2.73)

0.99

Q4, 0.66, 2.48 Z

0.68 (0.26, 1.84)

0.45

1.09 (0.48, 2.49)

0.84

0.98 (0.27, 3.56)

0.97

1.18 (0.41, 3.36)

0.76

gFA, Per 1 SD (continuous)
0.78 (0.54, 1.12)
0.18
1.02 (0.77, 1.36)
0.89
0.91 (0.56, 1.46)
0.68 1.15 (0.79, 1.67) 0.46
Model 0 is unadjusted. Model 1 is adjusted for age, center, race, sex, education, and APOE ε4 status. Model 2 is additionally adjusted for late-life
(visit 5) BMI, diabetes, hypertension, coronary heart disease, and current smoking status. Sixteen participants included in model 1 were excluded
from model 2 due to missing one or more model 2 covariate. Model 3 is additionally adjusted for total combined annual family income. Thirteen
participants included in model 2 were excluded from model 3 due to missing household family income data. P-values for the gFA by race
interaction term derived from model 2 were 0.42 for the quartiled analysis and 0.13 for the continuous analysis.
Abbreviations: OR, odds ratio; Q1, quartile 1; Q2, quartile 2; Q3, quartile 3; Q4, quartile 4; SD, standard deviation.

Table S10. The association of white matter DTI gMD with elevated cortical amyloid.
General Mean Diffusivity
(gMD)

Model 0
N=336
Elevated Amyloid
OR (95% CI)

P

Model 1
N=336
Elevated Amyloid
OR (95% CI)

P

Model 2
N=320
Elevated
Amyloid
OR (95% CI)

P

Model 3
N=307
Elevated
Amyloid
OR (95% CI)

P

1 (ref)

--

Q1, -1.95, -0.73 Z
(reference)

1 (ref)

--

1 (ref)

--

1 (ref)

--

Q2, -0.71, -0.15 Z

0.62 (0.34, 1.14)

0.12

0.53 (0.27, 1.05)

0.07

0.49 (0.24, 1.00)

0.05

0.51 (0.24, 1.05) 0.07

Q3, -0.13, 0.58 Z

1.10 (0.60, 2.03)

0.76

0.78 (0.38, 1.62)

0.51

0.82 (0.38, 1.76)

0.61

0.80 (0.37, 1.73) 0.57

Q4, 0.62, 3.22 Z

0.79 (0.43, 1.44)

0.44

0.75 (0.30, 1.88)

0.54

0.80 (0.30, 2.13)

0.66

0.72 (0.27, 1.95) 0.52

gMD, Per 1 SD (continuous)

0.99 (0.80, 1.23)

0.94

0.91 (0.65, 1.28)

0.59

0.94 (0.66, 1.34)

0.73

0.92 (0.64, 1.32) 0.66

General Mean Diffusivity
(gMD)
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Black
(Model 0)
N=143
Elevated Amyloid
OR (95% CI)

P

White
(Model 0)
N=193
Elevated Amyloid
OR (95% CI)

P

Black
(Model 2)
N=138
Elevated
Amyloid
OR (95% CI)

P

White
(Model 2)
N=182
Elevated
Amyloid
OR (95% CI)

P

Q1, -1.95, -0.73 Z
(reference)

1 (ref)

--

1 (ref)

--

1 (ref)

--

Q2, -0.71, -0.15 Z

0.73 (0.31, 1.70)

0.47

0.53 (0.22, 1.29)

0.16

0.49 (0.17, 1.44)

0.20

0.37 (0.13, 1.06) 0.06

Q3, -0.13, 0.58 Z

3.65 (1.27, 10.52)

0.02

0.57 (0.24, 1.34)

0.20

2.71 (0.70,
10.55)

0.15

0.34 (0.11, 0.98) 0.05

Q4, 0.62, 3.22 Z

1.71 (0.55, 5.25)

0.35

0.69 (0.31, 1.54)

0.37

1.22 (0.22, 6.78)

0.82

0.46 (0.12, 1.78) 0.26

1 (ref)

--

gMD, Per 1 SD (continuous)
1.49 (0.98, 2.27)
0.06
0.96 (0.72, 1.26)
0.75 1.28 (0.69, 2.35)
0.44 0.72 (0.43, 1.22) 0.22
Model 0 is unadjusted. Model 1 is adjusted for age, center, race, sex, education, and APOE ε4 status. Model 2 is additionally adjusted for late-life
(visit 5) BMI, diabetes, hypertension, coronary heart disease, and current smoking status. Sixteen participants included in model 1 were excluded
from model 2 due to missing one or more model 2 covariate. Model 3 is additionally adjusted for total combined annual family income. Thirteen
participants included in model 2 were excluded from model 3 due to missing household family income data. P-values for the gMD by race
interaction term derived from model 2 were 0.02 for the quartiled analysis and 0.02 for the continuous analysis.
Abbreviations: OR, odds ratio; Q1, quartile 1; Q2, quartile 2; Q3, quartile 3; Q4, quartile 4; SD, standard deviation.

Table S11. The association of tract-specific white matter DTI measures (FA and MD) with
elevated cortical amyloid.
Diffusion Tensor Imaging (DTI) White
Matter Tract

FA
N=320
Elevated Amyloid
OR (95% CI)*

P

MD
N=320
Elevated Amyloid
OR (95% CI)*

P

Cingulate Gyrus Cingulum, Left

0.89 (0.69, 1.15)

0.38

0.75 (0.52, 1.08)

0.12

Cingulate Gyrus Cingulum, Right

1.00 (0.78, 1.29)

0.97

0.89 (0.64, 1.24)

0.51

Hippocampal Cingulate Gyrus, Left

0.92 (0.70, 1.22)

0.57

1.03 (0.76 1.41)

0.84

Hippocampal Cingulate Gyrus, Right

0.99 (0.75, 1.30)

0.94

1.00 (0.73, 1.36)

0.98

Superior Longitudinal Fasciculus, Left

1.12 (0.86, 1.45)

0.40

1.02 (0.75, 1.39)

0.89

Superior Longitudinal Fasciculus, Right

1.33 (1.02, 1.74)

0.03

0.92 (0.68, 1.25)

0.60

Splenium of the Corpus Callosum

0.91 (0.70, 1.19)

0.49

1.10 (0.81, 1.48)

0.55

Values represent odds of elevated cortical amyloid per SD increase in fractional anisotropy (FA) and
mean diffusivity (MD).
*
Logistic regression models were adjusted for age, center, race, sex, education, APOE ε4 status, and latelife (visit 5) BMI, diabetes, hypertension, coronary heart disease, and current smoking status (model 2).
Abbreviations: FA, fractional anisotropy; MD, mean diffusivity.
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Table S12. The association of tract-specific white matter DTI measures (FA and MD) with elevated cortical amyloid, stratified
by race.
Black
Diffusion Tensor Imaging (DTI)
White Matter Tract

FA
N=138
Elevated
Amyloid
OR (95% CI)*

P

White
MD
N=138
Elevated
Amyloid
OR (95% CI)*

P

FA
N=182
Elevated
Amyloid
OR (95% CI)*

P

MD
N=182
Elevated
Amyloid
OR (95% CI)*

P
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Cingulate Gyrus Cingulum, Left

0.67 (0.43, 1.05)

0.08

0.99 (0.53, 1.85)

0.97

1.02 (0.73, 1.44)

0.90

0.62 (0.38, 1.02)

0.06

Cingulate Gyrus Cingulum, Right

0.82 (0.52, 1.30)

0.40

1.01 (0.59, 1.74)

0.97

1.17 (0.83, 1.63)

0.36

0.82 (0.51, 1.31)

0.40

Hippocampal Cingulate Gyrus,
Left

0.95 (0.60, 1.50)

0.84

1.33 (0.82, 2.16)

0.25

0.91 (0.63, 1.31)

0.61

0.80 (0.51, 1.26)

0.34

Hippocampal Cingulate Gyrus,
Right

1.14 (0.74, 1.75)

0.56

1.09 (0.66, 1.82)

0.74

0.93 (0.62, 1.40)

0.74

0.83 (0.52, 1.33)

0.44

1.02 (0.64, 1.61)

0.94

1.33 (0.77, 2.29)

0.30

1.23 (0.88, 1.72)

0.23

0.92 (0.60, 1.41)

0.70

1.62 (1.02, 2.58)

0.04

0.96 (0.58, 1.58)

0.87

1.31 (0.92, 1.86)

0.14

0.85 (0.55, 1.31)

0.45

0.77 (0.50, 1.19)

0.24

1.52 (0.91, 2.54)

0.11

1.07 (0.72, 1.61)

0.73

0.82 (0.52, 1.29)

0.40

Superior Longitudinal Fasciculus,
Left
Superior Longitudinal Fasciculus,
Right
Splenium of the Corpus Callosum

Values represent odds of elevated cortical amyloid per SD increase in fractional anisotropy (FA) and mean diffusivity (MD).
*
Logistic regression models are adjusted for age, center, race, sex, education, APOE ε4 status, and late-life (visit 5) BMI, diabetes, hypertension,
coronary heart disease, and current smoking status (model 2).
Abbreviations: FA, fractional anisotropy; MD, mean diffusivity.

Figure S1. WMH volume among amyloid-negative and amyloid-positive participants.
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A standardized uptake value ratio (SUVR) >1.2 was considered amyloid positive (Amyloid+).

Figure S2. Cortical amyloid standardized uptake value ratio by WMH volume.
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A standardized uptake value ratio (SUVR) >1.2 was considered amyloid positive (+)
Abbreviations: Q1, quartile 1; Q2, quartile 2; Q3, quartile 3; Q4, quartile 4; Standardized Uptake Value
Ratio (SUVR)

